AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 36169032 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 459
Study 36169032 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 459
Study 34214499 — intervention group
Group type: EXPERIMENTAL
Intervention: NU‐FlexSIV Socket
Number of subjects: 30
Study 34214499 — intervention group
Group type: COMPARATOR
Intervention: Ischial Containment (IC) Socket
Number of subjects: 30
Study 35901377 — intervention group
Group type: EXPERIMENTAL
Intervention: PSYCHOPATHY.COMP
Number of subjects: 119
Study 35901377 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (Control)
Number of subjects: 119
Study 33831896 — intervention group
Group type: EXPERIMENTAL
Intervention: REx (1 set to failure of 12 exercises)
Number of subjects: 24
Study 33831896 — intervention group
Group type: EXPERIMENTAL
Intervention: AEx (walking at 65%‐70% heart rate max for 45 min)
Number of subjects: 24
Study 33831896 — intervention group
Group type: COMPARATOR
Intervention: SED (sedentary control)
Number of subjects: 24
Study 32334510 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 μg·kg-1 DEX infusion (n=24)
Number of subjects: 73
Study 32334510 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 μg·kg-1 DEX infusion (n=25)
Number of subjects: 73
Study 32334510 — intervention group
Group type: COMPARATOR
Intervention: Control group (saline infusion, n=24)
Number of subjects: 73
Study 35961362 — intervention group
Group type: EXPERIMENTAL
Intervention: RotaTeq (3 doses at 6, 10, and 14 weeks)
Number of subjects: 1144
Study 35961362 — intervention group
Group type: COMPARATOR
Intervention: Rotarix (2 doses at 6 and 10 weeks)
Number of subjects: 1144
Study 35961362 — intervention group
Group type: EXPERIMENTAL
Intervention: RotaTeq (2 doses at 6 and 10 weeks)
Number of subjects: 1144
Study 35961362 — intervention group
Group type: EXPERIMENTAL
Intervention: RotaTeq (3 doses)
Number of subjects: 1144
Study 35961362 — intervention group
Group type: COMPARATOR
Intervention: Rotarix (2 doses)
Number of subjects: 1144
Study 35961362 — intervention group
Group type: EXPERIMENTAL
Intervention: RotaTeq and Rotarix
Number of subjects: 1144
Study 35961362 — intervention group
Group type: EXPERIMENTAL
Intervention: RotaTeq
Number of subjects: 1144
Study 35961362 — intervention group
Group type: COMPARATOR
Intervention: Rotarix
Number of subjects: 1144
Study 33687531 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive static stretching training (PST) for plantarflexor muscles (5×45 s-on/15 s-off)×2 exercises, 5 times/week for 12 weeks
Number of subjects: 30
Study 33687531 — intervention group
Group type: COMPARATOR
Intervention: Control group (no PST)
Number of subjects: 30
Study 32304486 — intervention group
Group type: EXPERIMENTAL
Intervention: IOL exchange with retropupillary fixation of an iris-claw IOL (n = 44 for ECD measurement)
Number of subjects: 104
Study 32304486 — intervention group
Group type: COMPARATOR
Intervention: IOL repositioning by scleral suturing (n = 50 for ECD measurement)
Number of subjects: 104
Study 33462302 — intervention group
Group type: EXPERIMENTAL
Intervention: HDP
Number of subjects: 4584
Study 32491276 — intervention group
Group type: EXPERIMENTAL
Intervention: TAPVC group
Number of subjects: 69
Study 32491276 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoplastic left heart syndrome, endocardial cushion defect, conotruncal defect groups
Number of subjects: 69
Study 32491276 — intervention group
Group type: COMPARATOR
Intervention: Ventricular septal defect group
Number of subjects: 69
Study 35775313 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab monotherapy
Number of subjects: 0
Study 35775313 — intervention group
Group type: COMPARATOR
Intervention: Adjuvant chemotherapy plus trastuzumab
Number of subjects: 0
Study 34027637 — intervention group
Group type: EXPERIMENTAL
Intervention: 1:1 I:E ratio ventilation
Number of subjects: 48
Study 34027637 — intervention group
Group type: COMPARATOR
Intervention: 1:2 I:E ratio ventilation
Number of subjects: 48
Study 32233747 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioid users (OU)
Number of subjects: 506
Study 32233747 — intervention group
Group type: COMPARATOR
Intervention: Alcohol and other drug users (AOD)
Number of subjects: 506
Study 35701752 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive rehearsal program delivered in five two-hour sessions over three weeks.
Number of subjects: 80
Study 35701752 — intervention group
Group type: COMPARATOR
Intervention: Control group received only written information about incivility.
Number of subjects: 80
Study 35701752 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive rehearsal program
Number of subjects: 80
Study 33411058 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunitinib
Number of subjects: 102
Study 34546436 — intervention group
Group type: EXPERIMENTAL
Intervention: Undermining (2 cm)
Number of subjects: 50
Study 34546436 — intervention group
Group type: COMPARATOR
Intervention: Non-undermined
Number of subjects: 50
Study 32895345 — intervention group
Group type: EXPERIMENTAL
Intervention: Life Respect Enhancement Program
Number of subjects: 56
Study 32895345 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 56
Study 35253265 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Number of subjects: 0
Study 35253265 — intervention group
Group type: EXPERIMENTAL
Intervention: Model-based inference
Number of subjects: 0
Study 35253265 — intervention group
Group type: EXPERIMENTAL
Intervention: Model-assisted inference
Number of subjects: 0
Study 35253265 — intervention group
Group type: EXPERIMENTAL
Intervention: Model-based estimators
Number of subjects: 0
Study 35253265 — intervention group
Group type: EXPERIMENTAL
Intervention: Model-assisted estimators
Number of subjects: 0
Study 34425533 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy (IC) followed by concurrent chemoradiotherapy (CCRT)
Number of subjects: 228
Study 34425533 — intervention group
Group type: COMPARATOR
Intervention: Concurrent chemoradiotherapy (CCRT) alone
Number of subjects: 228
Study 33238730 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive social and care interactions
Number of subjects: 379
Study 33238730 — intervention group
Group type: EXPERIMENTAL
Intervention: Care-related interactions
Number of subjects: 379
Study 33238730 — intervention group
Group type: EXPERIMENTAL
Intervention: One-on-one interactions
Number of subjects: 379
Study 33238730 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactions with nursing staff
Number of subjects: 379
Study 33238730 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactions with support staff
Number of subjects: 379
Study 33238730 — intervention group
Group type: EXPERIMENTAL
Intervention: Close interpersonal distance
Number of subjects: 379
Study 32065856 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Number of subjects: 92
Study 32065856 — intervention group
Group type: EXPERIMENTAL
Intervention: Pralatrexate
Number of subjects: 92
Study 32065856 — intervention group
Group type: EXPERIMENTAL
Intervention: Romidepsin
Number of subjects: 92
Study 36045426 — intervention group
Group type: EXPERIMENTAL
Intervention: prednisolone plus colchicine
Number of subjects: 67
Study 36045426 — intervention group
Group type: COMPARATOR
Intervention: prednisolone plus cimetidine
Number of subjects: 67
Study 34868330 — intervention group
Group type: EXPERIMENTAL
Intervention: Maxing Xianchang Su
Number of subjects: 206
Study 34868330 — intervention group
Group type: COMPARATOR
Intervention: Lactulose oral solution
Number of subjects: 206
Study 35291694 — intervention group
Group type: EXPERIMENTAL
Intervention: IV alpha-1 antitrypsin (AAT) 120 mg/kg weekly
Number of subjects: 36
Study 35291694 — intervention group
Group type: EXPERIMENTAL
Intervention: IV alpha-1 antitrypsin (AAT)
Number of subjects: 36
Study 35291694 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 34967397 — intervention group
Group type: EXPERIMENTAL
Intervention: Vedolizumab (VDZ)
Number of subjects: 419
Study 34967397 — intervention group
Group type: COMPARATOR
Intervention: Adalimumab (ADA)
Number of subjects: 419
Study 34029730 — intervention group
Group type: EXPERIMENTAL
Intervention: Big Stick Design (BSD)
Number of subjects: 0
Study 34029730 — intervention group
Group type: COMPARATOR
Intervention: Permuted Block Design (PBD)
Number of subjects: 0
Study 32295780 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care plus the structured transition programme
Number of subjects: 140
Study 32295780 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 140
Study 36307862 — intervention group
Group type: EXPERIMENTAL
Intervention: STARC-SUD (Skills Training in Affect Regulation – a Culture-sensitive approach)
Number of subjects: 286
Study 36307862 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 286
Study 33221910 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated CBTI with PAP adherence program
Number of subjects: 125
Study 33221910 — intervention group
Group type: COMPARATOR
Intervention: Sleep education control sessions
Number of subjects: 125
Study 32030488 — intervention group
Group type: EXPERIMENTAL
Intervention: p48MW HPC flow diverter with SAPT
Number of subjects: 8
Study 34631601 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard treatment with emollients and topical corticosteroids plus dilute bleach baths (DBB)
Number of subjects: 28
Study 34631601 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment with emollients and topical corticosteroids
Number of subjects: 28
Study 32318749 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal dexmedetomidine (5 μg, added to local anesthetics)
Number of subjects: 50
Study 32318749 — intervention group
Group type: COMPARATOR
Intervention: Intravenous dexmedetomidine (1 μg/kg infused during 10 min before blockade)
Number of subjects: 50
Study 36245293 — intervention group
Group type: EXPERIMENTAL
Intervention: Ozone gas
Number of subjects: 30
Study 36245293 — intervention group
Group type: COMPARATOR
Intervention: 1% chlorhexidine (CHX) gel
Number of subjects: 30
Study 32075834 — intervention group
Group type: EXPERIMENTAL
Intervention: Pramipexole
Number of subjects: 104
Study 32075834 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 104
Study 35673524 — intervention group
Group type: EXPERIMENTAL
Intervention: AMI Choice conversation tool
Number of subjects: 106
Study 35673524 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 106
Study 35673524 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 106
Study 35266342 — intervention group
Group type: EXPERIMENTAL
Intervention: Discontinuation of inappropriate medications
Number of subjects: 2000
Study 32464216 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel trial strategies including comprehensive consumer engagement, core outcome sets, novel trial designs, streamlined data collection, cost-effectiveness evaluations, knowledge dissemination plans, and impact evaluation.
Number of subjects: 0
Study 35819327 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous alteplase added to EVT
Number of subjects: 633
Study 35819327 — intervention group
Group type: COMPARATOR
Intervention: EVT alone
Number of subjects: 633
Study 33200844 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG-PSN
Number of subjects: 120
Study 33200844 — intervention group
Group type: COMPARATOR
Intervention: BCG vaccine
Number of subjects: 120
Study 33200844 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 120
Study 36384392 — intervention group
Group type: EXPERIMENTAL
Intervention: Biopsy during emergency gastroscopy
Number of subjects: 150
Study 36384392 — intervention group
Group type: COMPARATOR
Intervention: No biopsy during emergency gastroscopy
Number of subjects: 150
Study 34332810 — intervention group
Group type: EXPERIMENTAL
Intervention: Stented distal urethroplasty (Group A)
Number of subjects: 28
Study 34332810 — intervention group
Group type: COMPARATOR
Intervention: Un-stented distal urethroplasty (Group B)
Number of subjects: 28
Study 34332810 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (stented and un-stented)
Number of subjects: 28
Study 34252576 — intervention group
Group type: EXPERIMENTAL
Intervention: Transluminal injection of foam sclerotherapy (TLFS) with endovenous laser ablation (EVLA)
Number of subjects: 197
Study 34252576 — intervention group
Group type: COMPARATOR
Intervention: Ultrasound-guided foam sclerotherapy (UGFS) with endovenous laser ablation (EVLA)
Number of subjects: 197
Study 32297754 — intervention group
Group type: EXPERIMENTAL
Intervention: Galantamine
Number of subjects: 120
Study 32297754 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized cognitive-behavioral therapy (CBT4CBT)
Number of subjects: 120
Study 32297754 — intervention group
Group type: COMPARATOR
Intervention: Standard methadone treatment
Number of subjects: 120
Study 34260595 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with benazepril (10 mg/day) and valsartan (160 mg/day)
Number of subjects: 612
Study 34260595 — intervention group
Group type: COMPARATOR
Intervention: Benazepril (20 mg/day)
Number of subjects: 612
Study 34260595 — intervention group
Group type: COMPARATOR
Intervention: Valsartan (320 mg/day)
Number of subjects: 612
Study 32249749 — intervention group
Group type: EXPERIMENTAL
Intervention: Super Skills for Life (SSL) intervention
Number of subjects: 67
Study 34218992 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine/naloxone (Bup/Nal) treatment for 12 weeks
Number of subjects: 152
Study 34218992 — intervention group
Group type: COMPARATOR
Intervention: Buprenorphine/naloxone (Bup/Nal) detoxification for up to 2 weeks
Number of subjects: 152
Study 34218992 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly drug counseling
Number of subjects: 152
Study 34174706 — intervention group
Group type: EXPERIMENTAL
Intervention: Unguided low intensity cognitive behaviour therapy
Number of subjects: 225
Study 34174706 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 225
Study 35886276 — intervention group
Group type: EXPERIMENTAL
Intervention: ATTACHTM parenting program
Number of subjects: 40
Study 33031566 — intervention group
Group type: EXPERIMENTAL
Intervention: Obesity class I (BMI 30.0-34.9)
Number of subjects: 7189
Study 33031566 — intervention group
Group type: EXPERIMENTAL
Intervention: Obesity classes II and III (BMI ≥35.0)
Number of subjects: 7189
Study 33031566 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-obese women (BMI 25.0-29.9)
Number of subjects: 7189
Study 32584630 — intervention group
Group type: EXPERIMENTAL
Intervention: Vandetanib
Number of subjects: 331
Study 32827399 — intervention group
Group type: EXPERIMENTAL
Intervention: Halotherapy (HT)
Number of subjects: 0
Study 33748852 — intervention group
Group type: EXPERIMENTAL
Intervention: AI‐ECG
Number of subjects: 258607
Study 33748852 — intervention group
Group type: EXPERIMENTAL
Intervention: AI‐ECG with age and sex adjustment
Number of subjects: 258607
Study 33748852 — intervention group
Group type: EXPERIMENTAL
Intervention: AI‐ECG in patients without hypertension
Number of subjects: 258607
Study 33748852 — intervention group
Group type: EXPERIMENTAL
Intervention: False-positive AI‐ECG
Number of subjects: 258607
Study 35032695 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab 300 mg every 2 weeks (q2w)
Number of subjects: 2912
Study 35032695 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab 300 mg weekly (qw)
Number of subjects: 2912
Study 35032695 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined dupilumab (q2w and qw)
Number of subjects: 2912
Study 35032695 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 2912
Study 35032695 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab q2w
Number of subjects: 2912
Study 35032695 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab qw
Number of subjects: 2912
Study 33130235 — intervention group
Group type: EXPERIMENTAL
Intervention: Verinurad (9mg) plus febuxostat (80mg) once daily for 24 weeks
Number of subjects: 60
Study 33130235 — intervention group
Group type: COMPARATOR
Intervention: Matched placebo once daily for 24 weeks
Number of subjects: 60
Study 32893745 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E and ginseng supplement (100 IU vitamin E, 67 mg Korean ginseng, and 40 mg Siberian ginseng)
Number of subjects: 69
Study 32893745 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study 36476543 — intervention group
Group type: EXPERIMENTAL
Intervention: Vasopressin (40 IU) with initial epinephrine
Number of subjects: 148
Study 36476543 — intervention group
Group type: COMPARATOR
Intervention: Placebo with initial epinephrine
Number of subjects: 148
Study 32174307 — intervention group
Group type: EXPERIMENTAL
Intervention: Diffusion-weighted MRI in normal pregnancies
Number of subjects: 40
Study 32174307 — intervention group
Group type: COMPARATOR
Intervention: Diffusion-weighted MRI in complicated pregnancies
Number of subjects: 40
Study 32174307 — intervention group
Group type: COMPARATOR
Intervention: Subgroup analysis of dysfunctional placentas
Number of subjects: 40
Study 32174307 — intervention group
Group type: COMPARATOR
Intervention: Correlation analysis
Number of subjects: 40
Study 35275874 — intervention group
Group type: EXPERIMENTAL
Intervention: Facial proprioceptive neuromuscular facilitation
Number of subjects: 40
Study 35275874 — intervention group
Group type: COMPARATOR
Intervention: Connective tissue massage
Number of subjects: 40
Study 34292203 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin 100 mg per day
Number of subjects: 44
Study 34292203 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 32525954 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (received chickens at the start of the study)
Number of subjects: 11
Study 32525954 — intervention group
Group type: COMPARATOR
Intervention: Control group (did not receive chickens until the end of the study)
Number of subjects: 11
Study 32525954 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (intervention and control)
Number of subjects: 11
Study 35437223 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral magnesium chloride (MgCl2) for at least 4 months
Number of subjects: 0
Study 35437223 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 35437223 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral magnesium chloride (MgCl2)
Number of subjects: 0
Study 33950735 — intervention group
Group type: EXPERIMENTAL
Intervention: Community health worker-led intervention
Number of subjects: 0
Study 33950735 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 35913424 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical sialogogue spray containing 1% malic acid
Number of subjects: 52
Study 35913424 — intervention group
Group type: COMPARATOR
Intervention: Placebo spray
Number of subjects: 52
Study 32924913 — intervention group
Group type: EXPERIMENTAL
Intervention: Pragmatic intervention including systematic FC distress screening, privileged contact with an oncology nurse, and liaison with family physician for high distress FCs
Number of subjects: 109
Study 32924913 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention details provided)
Number of subjects: 109
Study 32679405 — intervention group
Group type: EXPERIMENTAL
Intervention: Transoral surgery followed by low- or standard-dose, risk-adjusted post-operative therapy
Number of subjects: 120
Study 32856547 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-mg nicotine gum
Number of subjects: 14
Study 32856547 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-mg nicotine gum
Number of subjects: 14
Study 32856547 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 36394849 — intervention group
Group type: EXPERIMENTAL
Intervention: Avelumab plus talazoparib
Number of subjects: 223
Study 33159007 — intervention group
Group type: EXPERIMENTAL
Intervention: QL1 technique
Number of subjects: 34
Study 33159007 — intervention group
Group type: EXPERIMENTAL
Intervention: QL2 technique
Number of subjects: 34
Study 33159007 — intervention group
Group type: EXPERIMENTAL
Intervention: TOP QL3 technique
Number of subjects: 34
Study 33371454 — intervention group
Group type: COMPARATOR
Intervention: High LF (600 mg/day)
Number of subjects: 335
Study 33371454 — intervention group
Group type: COMPARATOR
Intervention: Low LF (200 mg/day)
Number of subjects: 335
Study 33371454 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0 mg/day)
Number of subjects: 335
Study 35578658 — intervention group
Group type: EXPERIMENTAL
Intervention: Favipiravir (FVP)
Number of subjects: 57
Study 35578658 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study 33836956 — intervention group
Group type: EXPERIMENTAL
Intervention: Spiritual care (SC) provided by pharmacists
Number of subjects: 251
Study 33836956 — intervention group
Group type: EXPERIMENTAL
Intervention: Avoidance of spiritual care (SC)
Number of subjects: 251
Study 33836956 — intervention group
Group type: EXPERIMENTAL
Intervention: Education and training on spiritual care (SC)
Number of subjects: 251
Study 35900605 — intervention group
Group type: EXPERIMENTAL
Intervention: Test gel containing propolis extract, nanovitamin C, and nanovitamin E applied 3 times/day for 4 weeks
Number of subjects: 22
Study 35900605 — intervention group
Group type: COMPARATOR
Intervention: Control gel applied 3 times/day for 4 weeks
Number of subjects: 22
Study 33782413 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral oestroprogestogen contraceptive (OC)
Number of subjects: 58
Study 33782413 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose combination of spironolactone-pioglitazone-metformin (SPIOMET)
Number of subjects: 58
Study 33782413 — intervention group
Group type: COMPARATOR
Intervention: Post-OC treatment
Number of subjects: 58
Study 33782413 — intervention group
Group type: COMPARATOR
Intervention: Post-SPIOMET treatment
Number of subjects: 58
Study 32291813 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 units of intradermal BTX‐A
Number of subjects: 30
Study 32291813 — intervention group
Group type: COMPARATOR
Intervention: Combined emollients and topical mid‐potency steroid
Number of subjects: 30
Study 36261447 — intervention group
Group type: EXPERIMENTAL
Intervention: NGF injection in masseter muscle
Number of subjects: 28
Study 36261447 — intervention group
Group type: COMPARATOR
Intervention: Isotonic saline injection in masseter muscle
Number of subjects: 28
Study 32701874 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplemented group (additional 5.1 MJ·d‐1)
Number of subjects: 30
Study 32701874 — intervention group
Group type: COMPARATOR
Intervention: Control group (habitual diet)
Number of subjects: 30